drugset / Trial / NCT00224497

A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease

NCT00224497

Phase 2 Completed 380 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to find out if SB-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate Alzheimer's disease. SB-742457 is a new treatment which is thought to increase the levels of certain chemicals in the brain that are often decreased in patients with Alzheimer's disease.

Timeline

Start
2005-09
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject intepirdine Small molecule

Indications